NCT06992830

Cardioneuroablation for Variant Angina

Active, enrolled NA Last updated 25 November 2025

What this trial tests

NA trial testing cardioneuroablation in Variant Angina in 16 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

7 February 2025

Primary endpoint
28 February 2027

28 February 2027

Quick facts

Lead sponsor	Zhibing Lu
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	7 February 2025
Primary completion	28 February 2027
Estimated completion	28 February 2027
Sites	1 location across China

Drugs / interventions tested

• cardioneuroablation

Conditions studied

• Variant Angina — all drugs for Variant Angina →

Sponsor

Zhibing Lu

Who can join

Adults 18 to 80, any sex, with Variant Angina. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Variant angina, also known as vasospastic angina, is a form of chest pain caused by temporary spasms of the coronary arteries, which reduce blood flow to the heart. These spasms often occur at rest and may lead to serious complications, including life-threatening heart rhythm problems and sudden cardiac death. While most patients improve with medications such as calcium channel blockers and nitrates, some continue to have symptoms despite treatment. In addition, some patients are unable or unwilling to take medications regularly, which further limits effective management. These cases are referred to as medication-refractory or drug-intolerant variant angina.

The autonomic nervous system, which controls involuntary functions like heart rate and blood vessel tone, is believed to play an important role in the development of coronary artery spasms. Recent research suggests that imbalances in autonomic activity, particularly excessive parasympathetic signals, may trigger these spasms.

Cardioneuroablation (CNA) is a minimally invasive procedure that uses a catheter to target specific nerve clusters called cardiac ganglionated plexi, located on the surface of the heart. These plexi are important centers of autonomic control and are mostly made up of parasympathetic nerve cells. Originally developed to treat conditions such as fainting spells and certain types of abnormal heart rhythms, CNA works by selectively reducing abnormal parasympathetic activity in the heart.

This study is designed to explore whether CNA can help relieve chest pain and reduce coronary spasms in patients with variant angina who do not respond to medications or cannot take them consistently. The study will evaluate the safety, practicality, and potential benefits of this approach as a new treatment option for a difficult-to-manage heart condition.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.